Shares of Delcath Systems (DCTH +4.7%) are halted as the FDA's Oncologic Drugs Advisory...

|About: Delcath Systems, Inc. (DCTH)|By:, SA News Editor

Shares of Delcath Systems (DCTH +4.7%) are halted as the FDA's Oncologic Drugs Advisory Committee meets to discuss its new drug application for marketing approval of its its Melblez Kit for Injection, which is used to treat patients with unresectable ocular melanoma metastatic to the liver. The stock had been hit hard last week after the FDA expressed concern over the treatment's high death rate.